Current Report Filing (8-k)
April 28 2014 - 10:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act of 1934
April
28, 2014
Date
of Report (Date of earliest event reported)
AGENUS INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
|
000-29089
|
06-1562417
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
3 Forbes Road
Lexington, MA
|
02421
|
(Address
of principal executive offices)
|
(Zip
Code)
|
781-674-4400
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other events
Agenus Inc. announced today that the company has entered into a
collaboration and license agreement with Merck, known as MSD outside the
United States and Canada, through a subsidiary, for the discovery and
development of therapeutic antibodies to immune checkpoints for the
treatment of cancer. Under the terms of the agreement, Agenus will
discover and optimize fully human antibodies against two undisclosed
Merck checkpoint targets using the 4-Antibody Retrocyte Display®
platform. Merck will be responsible for clinical development and
commercialization of candidates generated under the collaboration.
Under the terms of the agreement, Agenus is eligible to receive
approximately $100 million in potential payments associated with the
completion of certain clinical, regulatory and commercial milestones for
two candidates from Merck. In addition, Agenus is eligible to receive
royalty payments on worldwide product sales.
The full text of the press release issued in connection with the
announcement is being filed as Exhibit 99.1 to this current report on
Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is filed herewith:
99.1 Press Release dated April 28, 2014
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
AGENUS INC.
|
|
|
Date: April 28, 2014
|
By:
|
/s/ Garo H. Armen
|
|
|
|
Garo H. Armen
|
|
Chief Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Press Release dated April 28, 2014
|
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024